Literature DB >> 24347664

Left atrial volume and the benefit of cardiac resynchronization therapy in the MADIT-CRT trial.

Rafael Kuperstein1, Ilan Goldenberg, Arthur J Moss, Scott Solomon, Mikhail Bourgoun, Amil Shah, Scott McNitt, Wojciech Zareba, Robert Klempfner.   

Abstract

BACKGROUND: Left atrial volume (LAV) is an important marker of heart failure (HF) severity. We hypothesized that LAV independently correlates with clinical outcomes in patients who receive cardiac resynchronization therapy with a defibrillator (CRT-D) and can be used for improved risk assessment in this population. METHODS AND
RESULTS: The benefit of CRT-D versus defibrillator-only therapy in reducing the risk of HF or death was assessed by LAV (dichotomized at the upper quartile>52 mL/m2) among 1785 patients enrolled in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) study. Landmark analysis was used to evaluate the relationship between LAV response to CRT-D and subsequent clinical outcomes. Multivariable analysis showed that patients with a higher baseline LAV experienced 69% (P<0.001) and 59% (P=0.02) increased hazard for HF or death and for all-cause mortality, respectively, independently of baseline left ventricular volume. CRT-D was associated with a significant reduction in LAV compared with defibrillator-only therapy (-28% versus -10%, respectively; P<0.001). Landmark analysis showed that after CRT-D implantation each 1% reduction in LAV was independently associated with a corresponding 4% reduction in the hazard of subsequent HF or death (P<0.001). The assessment of LAV change after CRT implantation improved prediction of clinical response to the device compared with assessment of the corresponding changes in left ventricular volume.
CONCLUSIONS: LAV is an independent correlate of clinical outcomes in mildly symptomatic HF patients treated with CRT-D. CRT exerts pronounced reverse remodeling effects on the left atrium that independently correlate with improved clinical outcomes after device implantation. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00180271.

Entities:  

Keywords:  cardiac resynchronization therapy; heart failure

Mesh:

Year:  2013        PMID: 24347664     DOI: 10.1161/CIRCHEARTFAILURE.113.000748

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  11 in total

Review 1.  Current role of echocardiography in cardiac resynchronization therapy.

Authors:  Donato Mele; Matteo Bertini; Michele Malagù; Marianna Nardozza; Roberto Ferrari
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

Review 2.  Recent advances in the optimization of cardiac resynchronization therapy.

Authors:  Satish Chandraprakasam; Gina G Mentzer
Journal:  Curr Heart Fail Rep       Date:  2015-02

Review 3.  Is extensive atrial fibrosis in the setting of heart failure associated with a reduced atrial fibrillation burden?

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Pacing Clin Electrophysiol       Date:  2018-09-09       Impact factor: 1.976

4.  Left atrial size and function as assessed by computed tomography in cardiac resynchronization therapy: Association to echocardiographic and clinical outcome.

Authors:  Peter Bomholt Hansen; Anders Sommer; Bjarne Linde Nørgaard; Mads Brix Kronborg; Jens Cosedis Nielsen
Journal:  Int J Cardiovasc Imaging       Date:  2017-01-25       Impact factor: 2.357

5.  Left atrial reverse remodeling predicts long-term survival after cardiac resynchronization therapy.

Authors:  Sjoerd Bouwmeester; Thomas P Mast; Daniëlle C J Keulards; Anouk G W de Lepper; Ingeborg H F Herold; Lukas R Dekker; Frits W Prinzen; Patrick Houthuizen
Journal:  J Echocardiogr       Date:  2021-11-25

6.  Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy.

Authors:  Mattia Arrigo; Quynh A Truong; Jackie Szymonifka; Mercedes Rivas-Lasarte; Heli Tolppanen; Malha Sadoune; Etienne Gayat; Alain Cohen-Solal; Frank Ruschitzka; James L Januzzi; Jagmeet P Singh; Alexandre Mebazaa
Journal:  Europace       Date:  2017-11-01       Impact factor: 5.214

7.  Left ventricular response after cardiac resynchronization therapy is related to early left atrial volume reduction.

Authors:  In-Jeong Cho; Jae-Sun Uhm; Jaewon Oh; Jong-Ho Nam; Hee Tae Yu; Taehoon Kim; Boyoung Joung; Seok-Min Kang
Journal:  Korean J Intern Med       Date:  2020-02-06       Impact factor: 2.884

8.  Predictors of rhythm outcomes after cardiac resynchronization therapy in atrial fibrillation patients: When should we use an atrial lead?

Authors:  Sotirios Nedios; Michael Doering; Angeliki Darma; Johannes Lucas; Borislav Dinov; Arash Arya; Nikolaos Dagres; Gerhard Hindricks; Andreas Bollmann; Sergio Richter; Kerstin Bode
Journal:  Clin Cardiol       Date:  2020-12-09       Impact factor: 2.882

9.  Improvement in quality of life and cardiac function after catheter ablation for asymptomatic persistent atrial fibrillation.

Authors:  Naoaki Onishi; Shokan Kyo; Maki Oi; Toshikazu Jinnai; Maiko Kuroda; Yukiko Shimizu; Sari Imamura; Takeshi Harita; Suguru Nishiuchi; Koji Hanazawa; Toshihiro Tamura; Chisato Izumi; Yoshihisa Nakagawa; Kazuaki Kaitani
Journal:  J Arrhythm       Date:  2020-12-11

10.  Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment.

Authors:  Marco R Di Tullio; Min Qian; John L P Thompson; Arthur J Labovitz; Douglas L Mann; Ralph L Sacco; Patrick M Pullicino; Ronald S Freudenberger; John R Teerlink; Susan Graham; Gregory Y H Lip; Bruce Levin; Jay P Mohr; Richard Buchsbaum; Conrado J Estol; Dirk J Lok; Piotr Ponikowski; Stefan D Anker; Shunichi Homma
Journal:  ESC Heart Fail       Date:  2018-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.